Skip to Content

NeuroBo is focused on developing and commercializing multi-modal disease-modifying therapies for cardiometabolic, viral, neuropathic, and neurodegenerative diseases. The company’s current pipeline consists of six programs targeting NASH, T2D, Obesity, COVID-19, Neuropathic Pain, Alzheimer’s disease and Dementia.